The aim of our study was to further evaluate the incidence of SDHD promoter mutations in a large cohort of melanoma samples of various subtypes and to investigate associations of SDHD mutation status with clinico-pathologic variables and other common oncogenic mutations in melanoma, such as BRAF, NRAS, KIT and TERT promoter mutations. Here, NRAS is linked to melanoma.